Preparation of quercetin long-circulating liposomes and their therapeutic effect on diabetic peripheral neuropathy

1. Tomic D, Shaw JE, Magliano DJ (2022) The burden and risks of emerging complications of diabetes mellitus. Nat Rev Endocrinol 18(9):525–539. https://doi.org/10.1038/s41574-022-00690-710.1038/s41574-022-00690-7 ↗

2. Elafros MA, Andersen H, Bennett DL, Savelieff MG, Viswanathan V, Callaghan BC et al (2022) Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments. Lancet Neurol 21(10):922–93610.1016/S1474-4422(22)00188-0 ↗

3. Zhu J, Hu Z, Luo Y, Liu Y, Luo W, Du X et al (2024) Diabetic peripheral neuropathy: pathogenetic mechanisms and treatment. Front Endocrinol (Lausanne). 14. https://doi.org/10.3389/fendo.2023.126537210.3389/fendo.2023.1265372 ↗

4. Kim YJ, Lee JM, Lee CW, Chung CH, Lee JH, Ko SH et al (2022) Analysis of clinical phenotypes of neuropathic symptoms in patients with type 2 diabetes: a multicenter study. Journal of Diabetes Investigation 13(11):1852–1860. https://doi.org/10.1111/jdi.1388010.1111/jdi.13880 ↗

5. Grisold A, Callaghan BC, Feldman EL (2017) Mediators of diabetic neuropathy: is hyperglycemia the only culprit? Curr Opin Endocrinol Diabetes Obes 24(2):103–111. https://doi.org/10.1097/med.000000000000032010.1097/med.0000000000000320 ↗

6. Iqbal Z, Azmi S, Yadav R, Ferdousi M, Kumar M, Cuthbertson DJ et al (2018) Diabetic peripheral neuropathy: epidemiology, diagnosis, and pharmacotherapy. Clin Ther 40(6):828–849. https://doi.org/10.1016/j.clinthera.2018.04.00110.1016/j.clinthera.2018.04.001 ↗

7. Frampton JE, Scott LJ (2004) Pregabalin - In the treatment of painful diabetic peripheral neuropathy. Drugs 64(24):2813–2820. https://doi.org/10.2165/00003495-200464240-0000610.2165/00003495-200464240-00006 ↗

8. Zou H, Ye H, Kamaraj R, Zhang T, Zhang J, Pavek P (2021) A review on pharmacological activities and synergistic effect of quercetin with small molecule agents. Phytomedicine 92. https://doi.org/10.1016/j.phymed.2021.15373610.1016/j.phymed.2021.153736 ↗

9. Pan B, Fang S, Wang L, Pan Z, Li M, Liu L (2023) Quercetin: a promising drug candidate against the potential SARS-CoV-2-Spike mutants with high viral infectivity. Comput Struct Biotechnol J 21:5092–5098. https://doi.org/10.1016/j.csbj.2023.10.02910.1016/j.csbj.2023.10.029 ↗

10. Lesjak M, Beara I, Simin N, Pintac D, Majkic T, Bekvalac K et al (2018) Antioxidant and anti-inflammatory activities of quercetin and its derivatives. J Funct Foods 40:68–75. https://doi.org/10.1016/j.jff.2017.10.04710.1016/j.jff.2017.10.047 ↗

11. Massi A, Bortolini O, Ragno D, Bernardi T, Sacchetti G, Tacchini M et al (2017) Research progress in the modification of quercetin leading to anticancer agents. Molecules 22(8). https://doi.org/10.3390/molecules2208127010.3390/molecules22081270 ↗

12. Sun SW, Yu HQ, Zhang H, Zheng YL, Wang JJ, Luo L (2007) Quercetin attenuates spontaneous behavior and spatial memory impairment in D-galactose-treated mice by increasing brain antioxidant capacity. Nutr Res 27(3):169–175. https://doi.org/10.1016/j.nutres.2007.01.01010.1016/j.nutres.2007.01.010 ↗

13. Liu M, Li P, Huang L, Li M, Wei H, Yu Q et al (2022) Research on the indirect antiviral function of medicinal plant ingredient quercetin against grouper iridovirus infection. Fish Shellfish Immunol 124:372–379. https://doi.org/10.1016/j.fsi.2022.04.01310.1016/j.fsi.2022.04.013 ↗

14. Xie J, Song W, Liang X, Zhang Q, Shi Y, Liu W et al (2020) Protective effect of quercetin on streptozotocin-induced diabetic peripheral neuropathy rats through modulating gut microbiota and reactive oxygen species level. Biomed Pharmacother 127. https://doi.org/10.1016/j.biopha.2020.11014710.1016/j.biopha.2020.110147 ↗

15. Zhang Q, Song W, Zhao B, Xie J, Sun Q, Shi X et al (2021) Quercetin attenuates diabetic peripheral neuropathy by correcting mitochondrial abnormality via activation of AMPK/PGC-1α pathway in vivo and in vitro. Front Neurosci 15. https://doi.org/10.3389/fnins.2021.63617210.3389/fnins.2021.636172 ↗

16. Zhao B, Zhang Q, Liang X, Xie J, Sun Q (2021) Quercetin reduces inflammation in a rat model of diabetic peripheral neuropathy by regulating the TLR4/MyD88/NF-κB signalling pathway. Eur J Pharmacol 912. https://doi.org/10.1016/j.ejphar.2021.17460710.1016/j.ejphar.2021.174607 ↗

17. Kandemir K, Tomas M, McClements DJ, Capanoglu E (2022) Recent advances on the improvement of quercetin bioavailability. Trends Food Sci Technol 119:192–200. https://doi.org/10.1016/j.tifs.2021.11.03210.1016/j.tifs.2021.11.032 ↗

18. Immordino ML, Dosio F, Cattel L (2006) Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed 1(3):297–315

19. Sathyamoorthy N, Dhanaraju MD (2016) Shielding therapeutic drug carriers from the mononuclear phagocyte system: a review. Crit Rev Ther Drug Carrier Syst 33(6):489–567. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.201601230310.1615/CritRevTherDrugCarrierSyst.2016012303 ↗

20. Gref R, Lück M, Quellec P, Marchand M, Dellacherie E, Harnisch S et al (2000) “Stealth” corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids and Surfaces B-Biointerfaces 18(3–4):301–313. https://doi.org/10.1016/s0927-7765(99)00156-310.1016/s0927-7765(99)00156-3 ↗

21. Cai Z, Wang Y, Zhu LJ, Liu ZQ (2010) Nanocarriers: a general strategy for enhancement of oral bioavailability of poorly absorbed or pre-systemically metabolized drugs. Curr Drug Metab 11(2):197–20710.2174/138920010791110836 ↗

22. Kwon GS, Kataoka K (2012) Block copolymer micelles as long-circulating drug vehicles. Adv Drug Del Rev 64:237–245. https://doi.org/10.1016/j.addr.2012.09.01610.1016/j.addr.2012.09.016 ↗

23. Albano JM, de Morais Ribeiro LN, Couto VM, Messias MB, da Silva GH, Breitkreitz MC, de Paula E, Pickholz M (2019) Rational design of polymer-lipid nanoparticles for docetaxel delivery. Colloids Surf B Biointerfaces 175:56–6410.1016/j.colsurfb.2018.11.077 ↗

24. Gorecki R, Antenucci F, Norinkevicius K, Christiansen LE, Myers ST, Trzaskus K et al (2021) Effect of detergents on morphology, size distribution, and concentration of copolymer-based polymersomes. Langmuir 37(6):2079–2090. https://doi.org/10.1021/acs.langmuir.0c0304410.1021/acs.langmuir.0c03044 ↗

25. Pernia Leal M, Munoz-Hernandez C, Berry CC, Luisa G-M (2015) In vivo pharmacokinetics of T2 contrast agents based on iron oxide nanoparticles: optimization of blood circulation times. RSC Adv 5(94):76883–76891. https://doi.org/10.1039/c5ra15680g10.1039/c5ra15680g ↗

26. Dobretsov M, Romanovsky D, Stimers JR (2007) Early diabetic neuropathy: triggers and mechanisms. World J Gastroenterol 13(2):175–191. https://doi.org/10.3748/wjg.v13.i2.17510.3748/wjg.v13.i2.175 ↗

27. Furse S (2022) Lipid metabolism is dysregulated in a mouse model of diabetes. Metabolomics 18(6). https://doi.org/10.1007/s11306-022-01884-w10.1007/s11306-022-01884-w ↗

28. Lin Q, Li K, Chen Y, Xie J, Wu C, Cui C et al (2023) Oxidative stress in diabetic peripheral neuropathy: pathway and mechanism-based treatment. Mol Neurobiol 60(8):4574–4594. https://doi.org/10.1007/s12035-023-03342-710.1007/s12035-023-03342-7 ↗

29. Stino AM, Rumora AE, Kim B, Feldman EL (2020) Evolving concepts on the role of dyslipidemia, bioenergetics, and inflammation in the pathogenesis and treatment of diabetic peripheral neuropathy. J Peripher Nerv Syst 25(2):76–8410.1111/jns.12387 ↗

30. Hangping Z, Ling H, Lijin J, Wenting Z, Xiaoxia L, Qi Z, Xiaoming Z, Qingchun L, Yiming L, Qian X, Ji H (2020) The preventive effect of IL-1beta antagonist on diabetic peripheral neuropathy. Endocr Metab Immune Disord Drug Targets (Formerly Current Drug Targets-Immune, Endocrine and Metabolic Disorders) 20(5):753–910.2174/1871530319666191022114139 ↗

31. X S, Y C, L N, G X. - Beneficial effect of TNF-α inhibition on diabetic peripheral neuropathy. D - 101222974. (- 1742–2094 (Electronic)):- 69.

32. Gonçalves NP, Vægter CB, Andersen H, Østergaard L, Calcutt NA, Jensen TS (2017) Schwann cell interactions with axons and microvessels in diabetic neuropathy. Nat Rev Neurol 13(3):135–4710.1038/nrneurol.2016.201 ↗

33. B B. - The LKB1-AMPK and mTORC1 metabolic signaling networks in Schwann cells control. D - 8510851. (- 1521–1878 (Electronic)):- e1800075.

34. Mantovani A, Byrne CD, Bonora E, Targher G (2018) Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care 41(2):372–382. https://doi.org/10.2337/dc17-190210.2337/dc17-1902 ↗

35. Godoy-Matos AF, Silva Junior WS, Valerio CM (2020) NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr 12:1. https://doi.org/10.1186/s13098-020-00570-y10.1186/s13098-020-00570-y ↗